To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
PPMI iPSCs
Human iPS Cell
Induced pluripotent stem cell (iPSC) lines are available through the PPMI repository. The repository includes lines from control, idiopathic PD, genetic PD (LRRK2, GBA, SNCA), genetic unaffected carriers (LRRK2, LRRK2/GBA, GBA, SNCA), and prodromal patients. Gene-revertant controls are available for select lines. An inventory of available lines can be found here: https://zenodo.org/records/10783308
Rab 10 Protein
Protein
Rab10 synthetic protein fragment (AA66-181) generated by native chemical ligation of recombinant peptides. To be used as a control with the pT73 Rab1o protein. This protein was designed and generated by X'PROCHEM.
pT73 Rab 10 Protein
Protein
Phospho-T73 Rab10 synthetic phosphomimetic protein fragment (AA66-181) generated by native chemical ligation of recombinant peptides. This protein was designed and generated by X'PROCHEM.
GBA1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in GBA1, including heterozygous and homozygous N370S and E326K mutations, among others. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP).*Heterozygous and homozygous L444P and Noncoding (rs3115534) mutations are currently in development. Estimated Availability: Q1 2026.
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic